Your session is about to expire
← Back to Search
Other
Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo
Phase 2
Waitlist Available
Research Sponsored by Sun Pharma Global FZE
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 52
Summary
This trial is testing a new treatment to ensure unbiased results. The study is conducted across various locations and countries.
Eligible Conditions
- Vitiligo
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ week 52
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 52
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Mean change from baseline in Vitiligo Area Scoring Index score
Secondary study objectives
Mean change from baseline in Vitiligo Extent Score
Mean change in Vitiligo Impact Patient scale
Mean change, from baseline, in Dermatology Life Quality Index
+1 moreTrial Design
5Treatment groups
Experimental Treatment
Placebo Group
Group I: AS012 dose regimen IVExperimental Treatment1 Intervention
Oral
Group II: AS012 dose regimen IIIExperimental Treatment1 Intervention
Oral
Group III: AS012 dose regimen IIExperimental Treatment1 Intervention
Oral
Group IV: AS012 dose regimen IExperimental Treatment1 Intervention
Oral
Group V: PlaceboPlacebo Group1 Intervention
Oral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AS012
2021
Completed Phase 2
~330
Find a Location
Who is running the clinical trial?
Sun Pharma Global FZELead Sponsor
33 Previous Clinical Trials
9,822 Total Patients Enrolled
Sun Pharmaceutical Industries LimitedLead Sponsor
69 Previous Clinical Trials
13,489 Total Patients Enrolled